CorMedix Inc.
CorMedix Inc. (NASDAQ: CORX) is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The company's website is www.cormedix.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What CorMedix Inc. does
In the company’s own words
CorMedix Inc. (NASDAQ: CORX) is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The company's website is www.cormedix.com.
CorMedix operates primarily through its commercial portfolio of antimicrobial and cardiovascular products. The company's flagship product is DefenCath, an antimicrobial catheter lock solution combining taurolidine and heparin, approved by the FDA to reduce catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through central venous catheters. DefenCath launched commercially in April 2024 in the inpatient setting and July 2024 in the outpatient hemodialysis setting, and represents the largest contributor to net sales.
In August 2025, CorMedix acquired Melinta Therapeutics, LLC, significantly expanding its commercial platform and product portfolio. The Melinta acquisition added six marketed infectious disease products: REZZAYO, a next-generation echinocandin for invasive fungal infections; MINOCIN IV, an intravenous tetracycline antibiotic; VABOMERE, a carbapenem combination therapy for resistant gram-negative infections; KIMYRSA and ORBACTIV, long-acting antibiotics for acute bacterial skin infections; and BAXDELA, a fluoroquinolone for serious infections. The acquisition also included TOPROL-XL, an established cardiovascular product. These products support a multi-channel strategy targeting hospital and clinic-based infectious disease treatment across emergency departments, outpatient clinics, and home infusion care settings.
CorMedix's business strategy focuses on maximizing value of its current portfolio while pursuing expanded indications for DefenCath and REZZAYO. The company is conducting a Phase 3 clinical study evaluating DefenCath for reducing bloodstream infections in patients receiving total parenteral nutrition and is obligated to conduct a pediatric hemodialysis study. REZZAYO is being evaluated for antifungal prophylaxis in blood and marrow transplant patients through the ReSPECT clinical trial, which completed enrollment in September 2025.
The company does not operate manufacturing facilities and outsources all production to third-party contract manufacturing organizations. CorMedix maintains partnerships with the Biomedical Advanced Research and Development Authority to advance BAXDELA and VABOMERE for pediatric use and biothreat applications, with total potential funding of $144.6 million through 2034.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- PARSIPPANY, NJ
- Fiscal year end
- December
- CIK
- 1410098
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns CorMedix Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · CorMedix Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
CorMedix Inc.’s bonds, as funds hold them
Funds report holding 1 issues of CorMedix Inc.’s debt, $3.19M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.00%, maturing 2030 to 2030.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do CorMedix Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of CorMedix Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in CorMedix Inc.'s last four quarterly filings that the numbers alone won't show?”